AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$CERS

Green Kevin Dennis sold $99K of CERS

Green Kevin Dennis (Chief Financial Officer) sold 33,676 shares of CERUS CORP (CERS) at $2.94 on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Green Kevin Dennis
Published Jul 2, 2026, 11:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
medium confidence
Mentioned
$CERS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The disclosed sale reduces insider holdings but is pre-arranged under Rule 10b5-1, which generally lowers the likelihood of a fundamental negative signal.

02

Market read

A routine 10b5-1 insider sale was newly disclosed; it is more relevant for sentiment monitoring than for a standalone trading catalyst.

03

What to watch

Traders should check whether there are concurrent insider buys/sales by other officers/directors and whether the company has any other same-day disclosures (earnings, guidance, financing).

Relevance 2/10Novelty 5/10Timing: new Form 4 filed after-hours/late day (2026-07-02)

Background

The article is an SEC Form 4 insider transaction filed by Cerus CFO Kevin Dennis.

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Cerus CFO Kevin Dennis filed a Form 4 open-market sale of 33,676 shares at $2.9429 on 2026-06-30 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any reaction should be short-lived unless accompanied by other new company-specific news.

Evidence & confidence

The filing is a Form 4 (primary disclosure) but specifies a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • company
    Cerus Corp

    Issuer of the Form 4 insider transaction; ticker CERS.

  • insider
    Green Kevin Dennis

    Cerus CFO who sold 33,676 shares in an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CERS insider trading history →

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min